No Data
No Data
Little Excitement Around ADC Therapeutics SA's (NYSE:ADCT) Revenues As Shares Take 27% Pounding
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q2 2024 Earnings Conference
ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its Second-Quarter Results
ADC Therapeutics Price Target Maintained With a $8.00/Share by RBC Capital
ADC Therapeutics Analyst Ratings
No Data